Generation of trans-dioxoruthenium(VI) porphyrins: A photochemical approach

trans-Dioxoruthenium(VI) porphyrin complexes have been developed as one of the best-characterized model systems for heme-containing enzymes. Traditionally, this type of compounds can be prepared by oxidation of ruthenium(II) precursors with peroxyacids and other terminal oxidants under different conditions, depending on the porphyrin ligands. In this work, a new photochemical generation of trans-dioxoruthenium(VI) porphyrins has been developed by extension of the known photo-induced ligand cleavage reactions. Refluxing ruthenium(II) carbonyl porphyrins [Ru^II(Por)(CO)] in carbon tetrachloride afforded dichlororuthenium(IV) complexes [Ru^IV(Por)Cl₂]. Facile exchange of the counterions in [Ru^IV(Por)Cl₂] with Ag(ClO₃) or Ag(BrO₃) gave the corresponding dichlorate [Ru^IV(Por)(ClO₃)₂] or dibromate [Ru^IV(Por)(BrO₃)₂] salts. Visible-light photolysis of the photo-labile porphyrin-ruthenium(IV) dichlorates or dibromates resulted in homolytic cleavage of the two O-Cl or O-Br bonds in the axial ligands to produce trans-dioxoruthenium(IV) species [Ru^VI(Por)O₂] bearing different porphyrin ligands.     

Carbonyl trichlorostannate complexes of platinum: chemistry and 119Sn, 195Pt,and 13C NMR spectroscopy

The reactions of the carbonyl anion [PtCl₃(CO)]^- with SnCl₂ in the presence of CO in both methylene chloride and acetone are reported. In the former solvent, only Pt^II-SnCl₃ species are formed. These have been identified by ¹³C, ¹¹⁹Sn and ¹⁹⁵Pt NMR measurements as cis-[PtCl₂(SnCl₃)(CO)]^-, (I), trans- [PtCl(SnCl₃)₂(CO)]^-, (II), and [Pt(SnCl₃)₄(CO)]^2-, (III). Salts of these complexes have been isolated. In contrast, when acetone is the solvent, reduction of the platinum occurs to give two new complexes. On the basis of NMR measurements, we assign one of these as the Pt^I dimer [Pt₂(SnCl₃)₄(CO)₂]^2-, (IV), and the other as a platinum triangle (VI) containing terminal CO ligands and two types of Sn ligand. The Pt^II compound (IV) can also be generated by treating a CH₂Cl₂ solution of trans-[PtCl(SnCl₃)_2- (CO)]^-, (II), with dihydrogen. NMR spectroscopic data, including those from measurements on samples of the complexes containing ¹³C-enriched CO, are reported and discussed.     

Reactivity of chloro(N-methyliminodiacetato)palladium(II) and chloro(pyridyl-2,6-dicarboxylato)palladium(II) complexes with purine based 5′-nucleotides and glutathione: antitumor activity of platinum(II)-analogs

The interaction of [Pd^II(mida)(Cl)]⁻ (1) (mida²⁻ = N-methyliminodiacetate) and [Pd^II(pydc)(Cl)]⁻ (2) (pydc²⁻ = pyridyl-2,6-dicarboxylate) with adenosine-5′-monophosphate (AMP), inosine-5′-monophosphate (IMP) and glutathione (GSH) was studied kinetically as a function of [L] (L = AMP, IMP, GSH) and [Cl⁻] and temperatures (10-35 °C) at pH 4.0. The kinetic results suggest that the reaction of 1 and 2 with the 5′-nucleotides (AMP, IMP) is characterized by the hydrolysis of chloro-complexes followed by the aquo-substitution with purine based 5′-nucleotides through its N7 atom. The reaction of 1 and 2 with GSH takes place through the direct chloride replacement with GSH. Kinetic data and activation parameters are interpreted in terms of an associative mechanism and discussed in reference to the data reported earlier. The [Pt^II(mida)(Cl)]⁻ (3) and [Pt^II(pydc)(Cl)]⁻ (4) complexes were prepared and allowed to interact with AMP and IMP and their reaction products were characterized by ¹H NMR studies. The antitumor activity of 3 and 4 was examined against MCF-7 (breast cancer), NCI-H460 (lung cancer) and SF-268 (CNS) cell lines.     

Computational study on the mechanisms of action of the potential anticancer drug trans-isopropylaminedimethylaminedichloroplatinum (trans-IPADMADP) and its cis isomer with DNA purine bases

The monofunctional and bifunctional bindings of the potential anticancer drug trans-isopropylaminedimethylaminedichloroplatinum (trans-IPADMADP) and its cis isomer to purine base in DNA are explored by using density functional theory and IEF-PCM solvation models. The computed lowest free energy barrier in the aqueous solution is 14.0/11.6 kcal/mol (from trans-Pt-chloroaqua complex to trans-/cis-monoadduct) for guanine(G), and 11.7/13.3 kcal/mol (from trans-Pt-chloroaqua complex to trans-/cis-monoadduct) for adenine(A). Our calculations demonstrate that the trans reactant complexes (or isolated reactants) can generate trans- or cis-monoadducts via similar trigonal bipyramidal transition state structures, suggesting that the monoadducts can subsequently close to form the bifunctional intrastrand Pt-DNA adducts and simultaneously distort DNA in the similar way as cisplatin. Our calculations show that Pt(isopropylamine)(dimethylamine)G₂²⁺ head-to-head path has the lowest free energy of activation at 17.6 kcal/mol, closely followed by the Pt(isopropylamine)(dimethylamine)GA²⁺ head-to-head path at 19.6 kcal/mol when the monofunctional cis-Pt-G complex serves as the reactant; while the Pt(isopropylamine)(dimethylamine)G₂²⁺ head-to-tail adduct has the lowest barrier of 20.5 kcal/mol, closely followed by the Pt(isopropylamine)(dimethylamine)GA²⁺ head-to-tail adduct at 23.0 kcal/mol if the monofunctional trans-Pt-G complex is the reactant.The calculated relatively lower activation energy barrier than that of cisplatin theoretically confirm that trans-[PtCl₂(isopropylamine)(dimethylamine)] is a potential anticancer drug as described by experiment.     

Is it homogeneous Pt(II) or heterogeneous Pt(0)n catalysis? Evidence that Pt(1,5-COD)Cl2 and Pt(1,5-COD)(CH3)2 plus H2 form heterogeneous,nanocluster plus bulk-metal Pt(0) hydrogenation catalysts

An investigation of the question of “Is it homogeneous or heterogeneous catalysis?” is reported when using Pt^II(1,5-COD)X₂ (X = halogen, alkyl) precatalysts for the hydrogenation of olefins. Using product studies, kinetic evidence, and Hg⁰ poisoning experiments, it is shown that Pt^II(1,5-COD)Cl₂ is a precatalyst and must be reduced to Pt⁰ nanoclusters and bulk metal as the true hydrogenation catalyst. An investigation of the related complex Pt^II(1,5-COD)(CH₃)₂ reveals that this complex does not form a hydrogenation catalyst by itself under H₂, in agreement with the literature. Kinetic and Hg⁰ poisoning evidence confirms that Pt^II(1,5-COD)(CH₃)₂, too, forms a Pt⁰ heterogeneous catalyst if other metals (Ir⁰, Pt⁰) are used as seeds to initiate the reduction of Pt^II. A short review of the use of Pt^II(1,5-COD)Cl₂ in hydrosilylation reactions is given, illustrating the continued controversy surrounding the nature of the true catalyst in that literature system.     

Copper-thioarylazoimidazole complexes: Structures, photochromism and redox interconversion between Cu(II) ↔ Cu(I) and correlation with DFT calculation

Reaction of Cu(ClO₄)₂·6H₂O, SRaaiNR′ (1-alkyl-2-[(o-thioalkyl)phenylazo]imidazole) and NH₄SCN (1:1:2 mol ratio) affords distorted square pyramidal, [Cu^II(SRaaiNR′)(SCN)₂] (3) compound while identical reaction with [Cu(MeCN)₄](ClO₄) yields -SCN- bridged coordination polymer, [Cu^I(SRaaiNR′)(SCN)]_n (4). These two redox states [Cu^II and Cu^I] are interconvertible; reduction of [Cu^II(SRaaiNR′)(SCN)₂] by ascorbic acid yields [Cu^I(SRaaiNR′)(SCN)]_n while the oxidation of [Cu^I(SRaaiNR′)(SCN)]_n by H₂O₂ in presence of excess NH₄SCN affords [Cu^II(SRaaiNR′)(SCN)₂]. They are structurally confirmed by single crystal X-ray diffraction study. Cyclic voltammogram of the complexes show Cu(II)/Cu(I) redox couple at ∼0.4 V and azo reductions at negative to SCE. UV light irradiation in MeCN solution of [Cu^I(SRaaiNR′)(SCN)]_n (4) show trans-to-cis isomerisation of coordinated azoimidazole. The reverse transformation, cis-to-trans, is very slow with visible light irradiation while the process is thermally accessible. Quantum yields (?_t→c) of trans-to-cis isomerisation are calculated and free ligands show higher ? than their Cu(I) complexes. The activation energy (E_a) of cis-to-trans isomerisation is calculated by controlled temperature experiment. Copper(II) complexes, 3, do not show photochromism. DFT and TDDFT calculation of representative complexes have been used to determine the composition and energy of molecular levels and results have been used to explain the solution spectra, photochromism and redox properties of the complexes.     

The rate of reduction of cis-, cis-, trans-[PtIV(NH2Pri)2Cl2(OH)2], CHIP,the anti-cancer drug by ascorbic acid

cis,cis,trans-[Pt^IV(NH₃)₂Cl₂(OH)₂] reacts reversibly with ascorbic acid to give dehydroascorbic acid and mainly cis-[Pt^II(NH₂Prⁱ)₂Cl₂]. The parameters for the forward reaction are: k_f = 0.584 M⁻ s⁻ at 37.0 °C, ΔH^≠_f = 108.6 −+ 6.4 kJ mol⁻¹ andΔS^≠_f = 101 −+ 22 J K⁻¹ mol⁻¹.     

Synthesis and the structure of mixed carboxylatoplatinum(IV) complexes involving one trifluoroacetate ligand

Mono(trifluoroacetato)platinum(IV) complexes of the formula [Pt^IV(dach)L₃(TFAc)] (dach = trans-(±)-1,2-diaminocyclohexane, TFAc = trifluoroacetate, L = acetate or propionate) could be prepared from the reaction of [Pt^IV(dach)L₃(OH)] with trifluoroacetic anhydride in the presence of a base and the crystal structure of compound 4 was determined by X-ray crystallography. In vitro antitumor activity of complex 4 (ED₅₀ = 3.1 μM) was found to be much higher than carboplatin (ED₅₀ = 10.2 μM).     

Photoactive trans ammine/amine diazido platinum(IV) complexes

The synthesis and characterisation of eight new octahedral Pt^IV complexes of the type trans,trans,trans-[Pt(N₃)₂(OH)₂(NH₃)(Am)] where Am = methylamine (2), ethylamine (4), thiazole (6), 2-picoline (8), 3-picoline (10), 4-picoline (12), cyclohexylamine (14), and quinoline (16) are reported, including the X-ray crystal structures of complexes 2, 8, and 14 as well as that of two of the precursor Pt^II complexes (trans-[Pt(N₃)₂(NH₃)(methylamine)] (1) and trans-[Pt(N₃)₂(NH₃)(cyclohexylamine)] (13)). Irradiation with UVA light rapidly induces loss in intensity of the azide-to-Pt^IV charge-transfer bands and gives rise to photoreduction of platinum. These complexes have potential for use as photoactivated anticancer agents.     

Binuclear monofunctional platinum(II) complexes formed by hexaazamacrocyclic bisdien ligands: Crystal structure, DNA binding and cytotoxicity studies

Two binuclear 3N-chelated monofunctional Pt^II complexes, [Pt₂L1Cl₂]Cl₂ (complex III) and [Pt₂L2Cl₂]Cl₂ (complex IV) [L1 = 3,6,9,16,19,22-hexaazatricyclo[22.2.2.2^11,14]-triaconta-11,13,24,26(1),27,29-hexaene, L2 = 3,6,9,17,20,23-hexaazatricyclo[23.3.1.1^11,15]-triaconta-1(29),11(30),12,14,25,27-hexaene] have been synthesized and structurally characterized. Structural determination revealed that each Pt^II center was coordinated by one chloride anion and three N atoms from each diethylenediamine motif. The Pt-Cl bonds in complex III are shorter than those found in complex IV. The rigid para- and meta-xylylene groups make the two complexes adopt a rigid boat-like conformation and a flexible twisted chair-like conformation, respectively. Moreover, complex III has higher tendency to bind with each other than complex IV. DNA binding studies demonstrated that complex IV could bind effectively with calf thymus DNA, possibly via platination of N7 of guanine residue, while no obvious DNA binding was observed for complex III. However, complex III displays a comparable cytotoxicity to cisplatin against HeLa cell line, while compound IV does not show any effective cell inhibition at low concentration. Therefore, the rigid spacers in complexes III and IV play a determining role in their anti-cancer activity and DNA binding ability.     

Synthesis of new (σ-N,N′-diazadiene)(η-alkene)platinum(0) compounds

Novel, thermally stable, dark-red to orange Pt⁰(σ²-N,N′-diazadiene)(η²-alkene) compounds have been synthesized in good yields from Pt⁰(COD)₂ or Pt⁰(NBE)₃, by stepwise substitution of the respective dienes or alkenes by an electron-poor alkene (dimethyl fumarate, maleic anhydride or fumaronitrile), followed by the appropriate diazadiene ligand in dry diethyl ether at 20 °C (diazadiene=various N,N′-disubstitued-1,4-diaza-1,3-dienes). The complex Pt(DBA)₂ is less suited as a precursor for the synthesis of Pt⁰(σ²-N,N′-diazadiene)(η²-alkene) compounds. These zerovalent Pt(diazadiene)(η²-alkene) compounds constitute a useful category of starting materials for synthetic organoplatinum chemistry and catalysis.     

Stepwise syntheses, structure and spectroscopic studies of ruthenium complexes of 2,6-bis(benzimidazol-2-yl)pyridine with o-iminoquinone ancillary ligand

The ruthenium complexes [Ru^II(bbp)(L)(Cl)] (1), [Ru^II(bbp)(L)(H₂O)] (2) and [Ru^II(bbp)(L)(DMSO)] (3) {bbp = 2,6-bis(benzimidazol-2-yl)pyridine, L = o-iminoquinone} have been synthesized in a stepwise manner starting from [Ru^III(bbp)Cl₃]. The single crystal X-ray structures, except for the complex 2, have been determined. All the complexes were characterized by UV-Vis, FT-IR, ¹H NMR, Mass spectroscopic techniques and cyclic voltammetry. The Ru^III/Ru^II couple for complexes 1, 2, and 3 appears at 0.63, 0.49, 0.55 V, respectively versus SCE. It is observed that complex 2, on refluxing in acetonitrile, results into [Ru^II(bbp)(L)(CH₃CN)], 4 which has been prepared earlier in a different method. The structural, spectral and electrochemical properties of complexes 1, 2 and 3 were compared to those of earlier reported complex 4, [Ru^II(bbp)(L)(CH₃CN)].     

Syntheses, structures and antimicrobial activities of various metal complexes of hinokitiol

Metal-oxygen bonding complexes (M = Mg^II, Mn^II, Ni^II, Mo^VI, W^VI, Pd^II, Sb^III, Bi^III, Fe^III, Ti^IV, K^I, Ba^II, Zr^IV and Hf^IV) with a hinokitiol (Hhino; 2-hydroxy-4-isopropylcyclohepta-2,4,6-trienone or β-thujaplicin) ligand, which has two unequivalent oxygen donor atoms, were synthesized and characterized by elemental analysis, TG/DTA, FT-IR and solution (¹H and ¹³C) NMR spectroscopy. Single-crystal X-ray structure analysis revealed various molecular structures for the complexes, which were classified into several families of family, i.e. type A [M^II(hino)₂(L)]₂ (M = Mg^II, Mn^II, Ni^II; L = EtOH or MeOH), with a dimeric structure consisting of one bridging hino⁻ anion, one chelating hino⁻ anion and one alcohol or water molecule, type B, with the octahedral, cis-dioxo, bis-chelate complexes cis-[M^VIO₂(hino)₂] (M = Mo^VI, W^VI), type C, with square planar complex [M^II(hino)₂] (M = Pd^II), type D, with tris-chelate, 7-coordinate complexes with one inert electron pair [M^III(hino)₃] (M = Sb^III, Bi^III), type D′, with the bis-chelate, pseudo-6-coordinate complexes with one inert electron pair [M^III(hino)₂X] (M = Sb^III, X = Br), type E, with tris-chelate, 6-coordinate complexes with Δ and Λ isomers [M^III(hino)₃] (M = Fe^III), type E′ of bis-chelate, 6-coordinate complex [M^IV(hino)₂X₂] (M = Ti^IV, X = Cl), type F, with water-soluble alkali metal salts [M^I(hino)] (M = K^I), and type H, with tetrakis-chelate, 8-coordinate complexes [M^IV(hino)₄](M = Zr^IV, Hf^IV). These structural features were compared with those of metal complexes with a related ligand, tropolone (Htrop). The antimicrobial activities of these complexes, evaluated in terms of minimum inhibitory concentration (MIC; μg mL⁻¹) in two systems, were compared to elucidate the relationship between structure and antimicrobial activity.     

fac-/mer-[RuCl3(NO)(P-N)] (P-N = [o-(N,N-dimethylamino)phenyl]diphenylphosphine): Synthesis, characterization and DFT calculations

Complex fac-[RuCl₃(NO)(P-N)] (1) was synthesized from the reaction of [RuCl₃(H₂O)₂(NO)] and the P-N ligand, o-[(N,N-dimethylamino)phenyl]diphenylphosphine) in refluxing methanol solution, while complex mer,trans-[RuCl₃(NO)(P-N)] (2) was obtained by photochemical isomerization of (1) in dichloromethane solution. The third possible isomer mer,cis-[RuCl₃(NO)(P-N)] (3) was never observed in direct synthesis as well as in photo- or thermal-isomerization reactions. When refluxing a methanol solution of complex (2) a thermally induced isomerization occurs and complex (1) is regenerated.The complexes were characterized by NMR (³¹P{¹H}, ¹⁵N{¹H} and ¹H), cyclic voltammetry, FTIR, UV-Vis, elemental analysis and X-ray diffraction structure determination. The ³¹P{¹H} NMR revealed the presence of singlet at 35.6 for (1) and 28.3 ppm for (2). The ¹H NMR spectrum for (1) presented two singlets for the methyl hydrogens at 3.81 and 3.13 ppm, while for (2) was observed only one singlet at 3.29 ppm. FTIR Ru-NO stretching in KBr pellets or CH₂Cl₂ solution presented 1866 and 1872 cm⁻¹ for (1) and 1841 and 1860 cm⁻¹ for (2). Electrochemical analysis revealed a irreversible reduction attributed to Ru^II-NO⁺ → Ru^II-NO⁰ at −0.81 V and −0.62 V, for (1) and (2), respectively; the process Ru^II → Ru^III, as expected, is only observed around 2.0 V, for both complexes.Studies were conducted using ¹⁵NO and both complexes were isolated with ¹⁵N-enriched NO. Upon irradiation, the complex fac-[RuCl₃(NO)(P-N)] (1) does not exchange ¹⁴NO by ¹⁵NO, while complex mer,trans-[RuCl₃(NO)(P-N)] (2) does. Complex mer,trans-[RuCl₃(¹⁵NO)(P-N)] (2′) was obtained by direct reaction of mer,trans-[RuCl₃(NO)(P-N)] (2) with ¹⁵NO and the complex fac-[RuCl₃(¹⁵NO)(P-N)] (1′) was obtained by thermal-isomerization of mer,trans-[RuCl₃(¹⁵NO)(P-N)] (2′).DFT calculation on isomer energies, electronic spectra and electronic configuration were done. For complex (1) the HOMO orbital is essentially Ru (46.6%) and Cl (42.5%), for (2) Ru (57.4%) and Cl (39.0%) while LUMO orbital for (1) is based on NO (52.9%) and is less extent on Ru (38.4%), for (2) NO (58.2%) and Ru (31.5%).     

Reactivity of [Ru(pac)(H2O)] (pac = polyaminocarboxylate) complexes with 5′-nucleotides and their antitumor activity

The reaction of [Ru^III(edta)(H₂O)]⁻ (edta⁴⁻ = ethylenediaminetetraacetate) and [Ru^III(hedtra)(H₂O)] (hedtra³⁻ = N-hydroxyethylethylenediaminetriacetate) with various purine based 5′-nucleotides (Nu) viz. adenosin-5′-monophosphate (AMP), guanosin-5′-monophosphate (GMP), inosin-5′-monophosphate (IMP) was studied kinetically as a function of [Nu] at various temperatures (15-35 °C) at a fixed pH (4.5). Kinetic results suggest that the binding of 5′-nucleotides takes place in a rapid [Nu] dependent rate-determining step. Kinetic data and activation parameters are accounted for the operation of an associative mechanism. The antitumor activities of both [Ru^III(edta)(H₂O)]⁻ (1) and [Ru^III(hedtra)(H₂O] (2) have been evaluated using MCF-7 (breast cancer), NCI-H460 (lung cancer) and SF-268 (CNS) cell lines.     

Triphos as a bidentate ligand: the reactivity of the dangling phosphorus in [PtMe2(triphos-P,P′)]

Complex [PtMe₂(triphos-P,P′)], (1) where the linear triphosphine triphos [=bis(diphenylphosphinoethyl)phenylphosphine] acts as a bidentate ligand, can be easily converted in a variety of new complexes due to the reactivity of the free phosphorus donor. The selective oxidation of the uncoordinated phosphorus gave [PtMe₂(triphosPO-P,P′)] whose X-ray crystal structure is here reported; from the reactions of 1 with platinum and non platinum precursors homotrimetallic [Pt₃Me₄XY(triphos)₂] (X=Y=Me, Cl, I, X=Me, Y=Cl) and heterotrimetallic ([Pt₂PdMe₄Cl₂(triphos)₂] and [Pt₂RhMe₄(cod)(triphos)₂]PF₆) complexes were obtained where triphos acts as a chelating/bridging ligand. When 1 was treated with triflic acid in the presence of a neutral electron donor L (L=SMe₂, pyridine, PPh₃), complexes [PtL(triphos)]²⁺ were rapidly recovered in high yields. The protonolysis of 1 in the presence of CO and methanol gave the new organometallic complex [Pt(COOMe)(triphos)]OTf.     

Modulation of trans-to-cis photoisomerization and photoluminescence of 1,2-bis(4-pyridyl)ethylene or 4-styrylpyridine coordinated to fac-tricarbonyl(5-chloro-1,10-phenathroline)rhenium(I)

Photochemical and photophysical properties of fac-[Re(CO)₃(Clphen)(trans-L)]⁺ complexes, Clphen = 5-chloro-1,10-phenathroline and L = 1,2-bis(4-pyridyl)ethylene, bpe, or 4-styrylpyridine, stpy, were investigated to complement the understanding of intramolecular energy transfer process in tricarbonyl rhenium(I) complexes having an electron withdrawing group attached to polypyridyl ligands. These new compounds were synthesized, characterized and the photoisomerization quantum yields were accurately determined by ¹H NMR spectroscopy. The true quantum yields for fac-[Re(CO)₃(Clphen)(trans-bpe)]⁺ were constant (Φ = 0.55) at all investigated irradiation wavelengths. However, for fac-[Re(CO)₃(Clphen)(trans-stpy)]⁺, similar true quantum yields were observed only at higher energy irradiation (Φ_{313 nm} = 0.53 and Φ_{365 nm} = 0.57), but it decreased significantly at 404 nm (Φ = 0.41). These results indicated different deactivation pathways for the trans-stpy complex photoisomerization. Quantum yields decreased as the ³IL_trans-L and ³MLCT_Re→NN excited states become closer and the behavior was discussed in terms of the excited state energy gaps. Additionally, luminescence properties of photoproducts, fac-[Re(CO)₃(Clphen)(cis-L)]⁺, were also investigated in different environments to analyze the relative energy of the ³MLCT_Re→Clphen excited state for each compound.     

Kinetics and mechanism of epoxidation of olefins by a novel ruthenium(IV)-oxo complex

[Ru^IV(tpy)(pic)(O)]⁺ (1) was synthesized by chemical oxidation of the corresponding aqua-complex [Ru^II(tpy)(pic)(H₂O)]⁺ (2) and characterized by analytical, spectroscopic (UV-vis and IR) and magnetic moment studies. Complex 1 effected epoxidation of styrene and substituted styrenes, cis- and trans-stilbenes and cyclohexene, in CH₃CN at room temperature. Epoxides were found to be the major product for styrenes and stilbenes, whereas, the oxidation of cyclohexene yielded allylic oxidation product. Detailed kinetic studies were performed under pseudo-first order conditions of excess alkene concentrations. A working mechanism in agreement with the rate and activation parameters is presented, and the results are discussed in reference to the data reported for the alkene oxidation by relevant Ru^IVO system in CH₃CN.     

Synthesis and structure of monoribbed-functionalized disulfide iron(II) clathrochelates and their coordination as the ligands toward platinum(II) and platinum(IV) ions

Disulfide monoribbed-functionalized clathrochelates (i.e., fuctionalization of one of the three α-dioximate fragments) with ribbed thioalkyl, S₃-thioalkyl and hydroxythioalkyl substituents have been synthesized starting from the FeBd₂(Cl₂Gm)(BF)₂ precursor (where Bd²⁻ and Cl₂Gm²⁻ are α-benzyldioxime and dichloroglyoxime dianions) using the corresponding thiol/triethylamine system in dichloromethane solution. Clathrochelate S₆-dithiol in basic media underwent the intramolecular dealkylation to yield the S₃-thiocrown etheric clathrochelate. Clathrochelates obtained have been studied as the ligands toward Pt²⁺ and Pt⁴⁺ ions. The S-demethylation reaction of the methylsulfide complex with [PtCl₄]²⁻ dianion produced the polynuclear complexes of the dianionic clathrochelate dithiolate ligand. The reaction of n-butylsulfide clathrochelate with the trans-Pt^IVCl₄(C₆H₅CH₂CN)₂ afforded the binuclear compound with the disulfide iron(II) clathrochelate as a monodentate ligand. The obtained macrobicycles, their clathrochelate derivatives, and polynuclear complexes have been characterized using elemental analysis, MALDI-TOF and PD mass, IR, UV-Vis, and NMR spectra, and X-ray crystallography. The encapsulated iron(II) ion coordination polyhedra distortion angle φ values and the main distances in the molecules of polynuclear complexes have been deduced (obtained) using ⁵⁷Fe Mössbauer parameters and EXAFS data, respectively.     

Synthesis and characterization of the novel Pt(II) complexes of the types cis- and trans-Pt(Ypy)(pyrazine)Cl2, K2[Cl3Pt(μ-pyrazine)PtCl3] and trans, trans-(Ypy)Cl2Pt(μ-pyrazine)Pt(Ypy)Cl2 (Ypy = pyridine derivative)

New types of Pt(II) mixed-ligand complexes containing a pyridine derivative (Ypy) and pyrazine (pz) were synthesized. The compounds were characterized by infrared spectroscopy and by multinuclear (¹H, ¹³C and ¹⁹⁵Pt) magnetic resonance. The complexes cis-Pt(Ypy)(pz)Cl₂ were synthesized from the reaction of K[Pt(Ypy)Cl₃] with pyrazine (1:1 proportion) in water. When the reaction was carried on in a 2:1 ratio, a mixture of compounds was obtained, which was refluxed in CH₂Cl₂ for several days. The final product was found to be pure and it was identified as trans,trans-Cl₂(Ypy)Pt(μ-pyrazine)Pt(Ypy)Cl₂. The cis monomers isomerize to the trans isomers in organic solvents. Different methyl derivatives of pyridine were studied in order to determine the influence of substitution in ortho position on the pyridine ligand in the complexes. In IR spectroscopy, the cis monomers showed two ν(Pt-Cl) bands, while the trans monomers and dinuclear species showed only one ν(Pt-Cl) band. The NMR results were interpreted in relation to the solvent effect, which seems important in these complexes. The ¹⁹⁵Pt NMR signals of the cis monomers were found at slightly higher fields than those of the corresponding trans isomers. The coupling constants J(¹⁹⁵Pt-¹H) and J(¹⁹⁵Pt-¹³C) are larger in the cis geometry. The δ(¹⁹⁵Pt) of the dinuclear species were found close to those of the trans monomers and the coupling constants are similar to those of the trans monomers, strongly suggesting a trans-trans configuration for the dinuclear compounds. The pyrazine-bridged complex K₂[Cl₃Pt(μ-pz)PtCl₃] was also synthesized and spectroscopically studied. The crystal structures of the compounds cis-Pt(3,5-lut)(pz)Cl₂ and trans-Pt(2,4,6-col)(pz)Cl₂ were determined by X-ray diffraction methods.